About Us
Meet the team
Editorial - scripnews.com
Principal Analysts
Marketing
Website
Key Accounts
Customer Retention
Publisher
|
Meet the team Editorial: scripnews.com Scrip Newsletter Principal Analysts Marketing Website Advertising Awards Key Accounts Customer Retention Publisher Editorial focus Contact us Subscription Renewals Customer Services Technical Support Advertising Head office US office Asia Editorial Office Japanese Sales Agent |
|
Scrip's editorial focus Established in 1972, Scrip World Pharmaceutical News is the leading source of global news in the pharmaceutical industry. Delivering an unrivalled range of pharma market intelligence, Scrip's network of experienced, locally based journalists provide you with a truly international and independent perspective. Scrip has a large independent editorial team of 21. The journalists are based throughout the world in Washington, Tokyo, India, and London to ensure a global emphasis to the latest news stories. • Science desk - The R&D section tracks the fortune of marketed and developmental drugs, from clinical data to their passage through the regulatory process. • Europe coverage - Scrip's Europe based desk covers all the political and regulatory developments that affect the pharmaceutical industry in the 27 member states, other European countries and the Russian Federation. • US coverage - Scrip's US team details the political developments from Washington affecting the global pharma industry, such as U.S. Food and Drug Administration safety and regulatory matters, as well as litigation, Generics and pharmacy. • World coverage - Scrip's locally based world coverage focuses on Japan and other Pacific Rim markets, Asia and Latin America. • Business news - Scrip's global reporters bring the latest information on financial and business affairs in the pharma and biotech sectors. • Analyst team - Scrip's analysts offer an insight into the industry's more significant developments. Their high-level strategic intelligence provide insight and argument on future issues affecting the pharma and biotech industries.
|
